Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement

Vasileios Chortis, Angela E. Taylor, Petra Schneider, Jeremy W. Tomlinson, Beverly A. Hughes, Donna M. O'Neil, Rossella Libé, Bruno Allolio, Xavier Bertagna, Jérôme Bertherat, Felix Beuschlein, Martin Fassnacht, Niki Karavitaki, Massimo Mannelli, Franco Mantero, Giuseppe Opocher, Emilio Porfiri, Marcus Quinkler, Mark Sherlock, Massimo Terzolo, Peter Nightingale, Cedric H. L. Shackleton, Paul M. Stewart, Stefanie Hahner, Wiebke Arlt
  • The Journal of Clinical Endocrinology & Metabolism, January 2013, Endocrine Society
  • DOI: 10.1210/jc.2012-2851

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1210/jc.2012-2851

The following have contributed to this page: Dr Niki Karavitaki and Prof Wiebke Arlt